Aamir Saifuddin1, Adam Harris1. 1. Department of Gastroenterology, Tunbridge Wells Hospital, Maidstone and Tunbridge Wells NHS Trust, Kent, UK.
Abstract
OBJECTIVE: To explore the 'real world' effectiveness of tacrolimus therapy for refractory ulcerative proctocolitis (UC). DESIGN: Retrospective cohort study using prospectively collated clinical data. SETTING: A single district general hospital in Kent, UK. Clinical decisions and regular monitoring were undertaken by a single expert in inflammatory bowel disease. PATIENTS: All patients started on tacrolimus between January 2010 and August 2016 at Tunbridge Wells Hospital. INTERVENTIONS: Following failure of conventional medication, tacrolimus was commenced at 0.5 mg/kg twice daily. Drug trough levels of 5-20 ng/mL were targeted. Other immunomodulation was stopped and steroids were weaned over 4-6 weeks. MAIN OUTCOME MEASURES: Treatment duration was measured for each patient. If the drug was stopped, the rationale, including specific side effects, was recorded. The patient's subsequent management plan was noted. RESULTS: Thirty-five patients were started on tacrolimus (range: 18-85, median: 36 years). Disease extent included proctitis to pancolitis. Twenty-five patients derived no benefit. Four patients responded, but drug side effects necessitated withdrawal. Eighteen of these 29 patients (62%) underwent surgery. One patient, who had previously responded, stopped the drug after becoming pregnant (healthy subsequent birth). Therefore, 5 of 35 patients (14%) remain on tacrolimus with sustained clinical response, ranging from 6 to 76 (median: 32) months of treatment. Treatment was most effective for proctosigmoiditis. There were no other demographic or biological markers for success. CONCLUSIONS: In line with UK and European guidelines, tacrolimus can be beneficial for refractory UC. With appropriate monitoring, it appears treatment can be continued safely long term.
OBJECTIVE: To explore the 'real world' effectiveness of tacrolimus therapy for refractory ulcerative proctocolitis (UC). DESIGN: Retrospective cohort study using prospectively collated clinical data. SETTING: A single district general hospital in Kent, UK. Clinical decisions and regular monitoring were undertaken by a single expert in inflammatory bowel disease. PATIENTS: All patients started on tacrolimus between January 2010 and August 2016 at Tunbridge Wells Hospital. INTERVENTIONS: Following failure of conventional medication, tacrolimus was commenced at 0.5 mg/kg twice daily. Drug trough levels of 5-20 ng/mL were targeted. Other immunomodulation was stopped and steroids were weaned over 4-6 weeks. MAIN OUTCOME MEASURES: Treatment duration was measured for each patient. If the drug was stopped, the rationale, including specific side effects, was recorded. The patient's subsequent management plan was noted. RESULTS: Thirty-five patients were started on tacrolimus (range: 18-85, median: 36 years). Disease extent included proctitis to pancolitis. Twenty-five patients derived no benefit. Four patients responded, but drug side effects necessitated withdrawal. Eighteen of these 29 patients (62%) underwent surgery. One patient, who had previously responded, stopped the drug after becoming pregnant (healthy subsequent birth). Therefore, 5 of 35 patients (14%) remain on tacrolimus with sustained clinical response, ranging from 6 to 76 (median: 32) months of treatment. Treatment was most effective for proctosigmoiditis. There were no other demographic or biological markers for success. CONCLUSIONS: In line with UK and European guidelines, tacrolimus can be beneficial for refractory UC. With appropriate monitoring, it appears treatment can be continued safely long term.
Authors: Paul Rutgeerts; William J Sandborn; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Suzanne Travers; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel Present; Bruce E Sands; Jean Frédéric Colombel Journal: N Engl J Med Date: 2005-12-08 Impact factor: 91.245
Authors: Jonathan Landy; Mahmood Wahed; Simon T C Peake; Mohammed Hussein; Siew C Ng; James O Lindsay; Ailsa L Hart Journal: J Crohns Colitis Date: 2013-04-25 Impact factor: 9.071
Authors: Brian G Feagan; Paul Rutgeerts; Bruce E Sands; Stephen Hanauer; Jean-Frédéric Colombel; William J Sandborn; Gert Van Assche; Jeffrey Axler; Hyo-Jong Kim; Silvio Danese; Irving Fox; Catherine Milch; Serap Sankoh; Tim Wyant; Jing Xu; Asit Parikh Journal: N Engl J Med Date: 2013-08-22 Impact factor: 91.245
Authors: Craig Mowat; Andrew Cole; Al Windsor; Tariq Ahmad; Ian Arnott; Richard Driscoll; Sally Mitton; Tim Orchard; Matt Rutter; Lisa Younge; Charlie Lees; Gwo-Tzer Ho; Jack Satsangi; Stuart Bloom Journal: Gut Date: 2011-05 Impact factor: 23.059